Pregnancy is a complex physiological state characterized by intricate immunological adaptations that allow the maternal immune system to tolerate the semi-allogeneic fetus. However, when a woman has an underlying autoimmune disorder, this delicate immunological balance can be disrupted, leading to potential complications for both mother and child. Autoimmune disorders in pregnancy represent a significant clinical challenge due to the interplay between chronic immune dysregulation and the unique immunological environment of gestation.
Understanding Autoimmune Disorders
Autoimmune diseases occur when the body’s immune system mistakenly attacks its own tissues. Normally, the immune system distinguishes between self and non-self antigens, ensuring that foreign pathogens are eliminated while avoiding damage to the host. In autoimmune conditions, this self-tolerance is compromised, leading to chronic inflammation and tissue destruction. There are over 80 recognized autoimmune disorders, which can affect virtually any organ system. The etiology of autoimmune diseases is multifactorial, involving genetic predisposition, environmental triggers (such as infections, toxins, or ultraviolet radiation), and hormonal influences. Notably, many autoimmune diseases are more prevalent in women, particularly those of reproductive age, suggesting a role for sex hormones in immune regulation.
The Immunological Landscape of Pregnancy
To appreciate how autoimmune disorders interact with pregnancy, it is vital to understand the normal immunological changes that occur during gestation. Pregnancy requires a shift from a pro-inflammatory (Th1-dominant) immune response to an anti-inflammatory, tolerance-promoting (Th2-dominant) state. This shift helps prevent rejection of the fetus, which carries paternal antigens foreign to the mother. Regulatory T cells (Tregs) play a crucial role in establishing maternal-fetal tolerance by suppressing effector immune responses. Additionally, changes in cytokine profiles, natural killer (NK) cell activity, and hormone levels—particularly elevated progesterone and estrogen—contribute to immune modulation.
In women with autoimmune disorders, this immunological shift may be impaired or excessively pronounced, depending on the specific disease and its activity. For example, some autoimmune conditions improve during pregnancy due to the anti-inflammatory milieu, while others may flare or remain stable.
Common Autoimmune Disorders in Pregnancy
Several autoimmune diseases are frequently encountered in pregnant women, and each presents distinct challenges:
- Systemic Lupus Erythematosus (SLE): SLE is a chronic multisystem inflammatory disease characterized by autoantibody production, notably anti-dsDNA and anti-Smith antibodies. Pregnancy in women with SLE carries increased risks, including lupus flares, preeclampsia, fetal loss, and neonatal lupus. The presence of antiphospholipid antibodies (aPL), such as lupus anticoagulant or anticardiolipin antibodies, further elevates the risk of thrombosis and recurrent miscarriages.
- Rheumatoid Arthritis (RA): RA is an autoimmune condition primarily affecting the joints. Interestingly, RA often improves during pregnancy, especially in the second and third trimesters, likely due to increased levels of anti-inflammatory hormones and Treg activity. However, postpartum flares are common, requiring close monitoring.
- Antiphospholipid Syndrome (APS): APS is an autoimmune disorder defined by the presence of antiphospholipid antibodies and clinical manifestations such as venous or arterial thrombosis and pregnancy morbidity (e.g., recurrent miscarriages, preterm birth, preeclampsia). It can occur alone (primary APS) or in association with SLE (secondary APS).
- Hashimoto’s Thyroiditis and Graves’ Disease: Both are autoimmune thyroid disorders. Hashimoto’s leads to hypothyroidism, while Graves’ causes hyperthyroidism. Uncontrolled thyroid dysfunction during pregnancy is linked to adverse outcomes such as miscarriage, preterm birth, and developmental delays in the fetus. Thyroid autoantibodies, even in euthyroid women, may slightly increase miscarriage risk.
- Multiple Sclerosis (MS): MS involves autoimmune-mediated demyelination of the central nervous system. Pregnancy is generally protective against MS relapses, particularly in the third trimester, but the postpartum period carries a higher relapse risk.
Risks and Complications for Mother and Fetus
Autoimmune disorders during pregnancy are associated with a range of maternal and fetal complications. Maternal risks include disease flares, preeclampsia, gestational diabetes, and thromboembolic events. For instance, women with SLE are at a 20-30% risk of developing preeclampsia, which can be difficult to distinguish from a lupus nephritis flare.
Fetal complications vary by condition but may include intrauterine growth restriction (IUGR), preterm delivery, congenital heart block (in neonatal lupus), and stillbirth. Neonatal lupus, a passively acquired condition, occurs when maternal anti-Ro/SSA and anti-La/SSB antibodies cross the placenta and affect the fetal conduction system, potentially leading to complete heart block. The risk is approximately 2% in antibody-positive mothers but increases with prior affected offspring.
Preconception Counseling and Planning
Optimal management begins before conception. Preconception counseling is critical for women with autoimmune disorders. Healthcare providers should assess disease activity, review medications for teratogenicity, and optimize organ function (e.g., renal, cardiac, endocrine). Ideally, pregnancy should be timed during periods of disease quiescence—typically at least 6 months of stable, low-disease activity. Medications such as methotrexate and mycophenolate mofetil must be discontinued prior to conception due to their high teratogenic potential.
Assessing antibody status (e.g., anti-Ro/SSA, anti-La/SSB, aPL) is essential, as these can predict fetal risks. Additionally, vaccinations (e.g., influenza, Tdap) should be updated, and folic acid supplementation should be initiated early.
Monitoring and Management During Pregnancy
Close monitoring by a multidisciplinary team—including rheumatologists, maternal-fetal medicine specialists, and neonatologists—is essential. Regular assessments of disease activity, blood pressure, renal function, and fetal well-being are performed throughout gestation.
Medication management requires balancing maternal health with fetal safety. Hydroxychloroquine is widely used in SLE and is considered safe in pregnancy, reducing flare risk and improving outcomes. Low-dose aspirin and heparin are standard in APS to prevent thrombosis and pregnancy loss. Corticosteroids may be used for disease flares but require cautious dosing due to risks of gestational diabetes and preterm birth.
Serial fetal echocardiograms are recommended for anti-Ro/SSA-positive mothers to detect early signs of conduction abnormalities. Doppler ultrasound may be used to assess placental function and fetal growth.
Delivery and Postpartum Care
The mode and timing of delivery depend on maternal and fetal conditions. In most cases, vaginal delivery is possible, but cesarean section may be indicated for obstetric complications. The postpartum period is a high-risk phase for disease flares, especially in SLE and RA. Close follow-up and mental health screening (due to increased depression risk) are crucial.
Breastfeeding is encouraged for most women, as many medications (e.g., hydroxychloroquine, azathioprine) are compatible with lactation. However, some drugs (e.g., cyclophosphamide) require temporary cessation.
Long-Term Outlook and Research Directions
With timely diagnosis, multidisciplinary care, and adherence to treatment, most women with autoimmune disorders can achieve successful pregnancies. Long-term data show that pregnancy does not typically worsen the overall prognosis of autoimmune diseases when managed appropriately. Ongoing research focuses on biomarkers for predicting flare risk, novel immunomodulatory therapies safe in pregnancy, and interventions to promote fetal tolerance.
Conclusion
Autoimmune disorders in pregnancy present unique challenges that demand a comprehensive, patient-centered approach. From preconception planning to postpartum care, effective management hinges on collaboration between specialties, vigilant monitoring, and individualized treatment. By understanding the immunological interplay between autoimmunity and pregnancy, healthcare providers can optimize outcomes for both mother and child, ensuring healthier futures for families navigating these complex conditions.
References
- Clowse, M. E. B., & Jamison, M. (2019). Rheumatology and Pregnancy: A Practical Guide. Springer.
- Buyon, J. P., et al. (2015). “An update on neonatal lupus syndromes.” Nature Reviews Rheumatology, 11(11), 651–663. https://doi.org/10.1038/nrrheum.2015.99
- Lockshin, M. D., & Kim, M. (2019). “Pregnancy in systemic lupus erythematosus.” Rheumatic Disease Clinics of North America, 45(1), 87–100. https://doi.org/10.1016/j.rdc.2018.08.006
- American College of Rheumatology. (2020). “Guidelines for Immunizations in Patients with Rheumatic Diseases.” https://www.rheumatology.org
- Lockwood, C. J., & Druzin, M. L. (2021). “Pregnancy in women with autoimmune disease.” UpToDate. Retrieved from https://www.uptodate.com
- Simard, J. F., et al. (2012). “An update on lupus and pregnancy.” Current Opinion in Rheumatology, 24(2), 112–117. https://doi.org/10.1097/BOR.0b013e32834f6d84
- Petri, M., et al. (2012). “International consensus for a definition of disease flare in lupus.” Lupus, 21(2), 145–152. https://doi.org/10.1177/0961203311429560
- Costedoat-Chalumeau, N., et al. (2009). “Hydroxychloroquine in lupus during pregnancy.” Annals of the Rheumatic Diseases, 68(8), 1377. https://doi.org/10.1136/ard.2008.094396
